First New Tourette Drug in a Decade Nears FDA Decision

An experimental medicine for Tourette syndrome is moving closer to US approval after new pediatric data showed that nearly seven in ten young patients achieved a clinically meaningful drop in tic severity within eight weeks of starting treatment. The analyses, presented at a movement disorders congress in Seoul this month, come as the drug sits under FDA priority review with a regulatory decision expected early next year, according to NeurologyLive's coverage of the trial data. If cleared, the New Tourette Drug would be the first new therapy for the condition in more than a decade, and the first to act through a fundamentally different brain mechanism in roughly half a century.

Tourette syndrome usually begins in childhood and is marked by sudden, repetitive movements and sounds that can be difficult to suppress. For many families, the current medication options are a difficult trade: the most common prescriptions work by blocking dopamine D2 receptors, a mechanism shared with antipsychotic medicines, and they can carry burdensome side effects including weight gain and movement disorders. As a result, about half of patients end up taking no medication at all, and many who do start stop within a year. Behavioral therapies remain the recommended first step, but access is limited and they do not work for everyone, as described in coverage of the drug's regulatory path.

What the new data show

The headline figures come from a pooled post hoc analysis of 292 participants across the drug's Phase 2b and Phase 3 studies. Clinically meaningful improvement was defined as a reduction of at least one quarter from baseline on the Yale Global Tic Severity Scale Total Tic Score, a standard clinician-rated measure of tic burden. By that bar, nearly seventy percent of participants reached meaningful improvement within two months of starting the medicine. The most commonly reported side effects during that window were drowsiness and headache, with the company noting that adverse events were mostly concentrated in the initial exposure period.

The benefit also appears to last. An interim analysis of an ongoing open-label extension study found that 118 children, adolescents and adults maintained clinically meaningful tic suppression through eighteen months of treatment, with no new safety signals emerging over the longer follow-up, according to the Seoul presentation. Subgroup analyses delivered another reassuring detail: improvements and safety looked similar whether or not participants also lived with ADHD, OCD, anxiety or depression, and there was no signal of psychiatric symptoms getting worse on the drug.

Those results build on the pivotal Phase 3 trial, known as D1AMOND, whose findings were published in JAMA Neurology. That study enrolled 216 people across 77 sites in twelve countries and used a randomized-withdrawal design: participants who had already shown a meaningful response during an initial open-label period were then randomly assigned to keep taking the medicine or switch to placebo. Over the next twelve weeks, those who stayed on the drug saw their risk of tic relapse fall by more than half compared with those who switched, a result the researchers described as statistically significant.

Why the mechanism matters

Ecopipam, the investigational medicine developed by Teva Pharmaceuticals, blocks dopamine D1 receptors rather than D2 receptors. Scientists believe that targeting D1 signaling dampens tic activity through the brain's direct motor pathway, offering a non-antipsychotic route to the same goal. Across the program, the company reports stability in weight and body-mass index, laboratory values, heart tracings and movement-disorder scales, a profile that stands apart from medicines acting through D2 blockade.

"Ecopipam's NDA acceptance is an important milestone ... and brings us closer to addressing the unmet needs of children and their families affected by Tourette syndrome," said Eric Hughes, Teva's executive vice president of global research and development and chief medical officer, in a statement. The company is advancing what it calls a pivot-to-growth strategy, and regulators have granted the drug orphan designation for the pediatric indication, a status reserved for medicines addressing conditions that affect relatively small patient populations.

Specialists who treat tics have long asked for a third path. The current pharmacologic playbook is narrow: older D2-blocking agents approved decades ago, plus a handful of blood-pressure medicines used off label. A first-in-class option with a different mechanism could give clinicians something to offer families who have exhausted behavioral therapy but are reluctant to accept antipsychotic side effects in a child.

What happens next

The timeline is now short. The FDA accepted Teva's new drug application in August and granted priority review, a faster track reserved for applications judged potentially capable of significant improvements in treatment. A decision is expected early next year, as reported by Contemporary Pediatrics. Filing acceptance means only that the application was complete enough for substantive review; the agency's benefit-risk determination still lies ahead.

For readers, a few cautions matter. The medicine remains investigational and is not approved anywhere. The early-response figures come from post hoc analyses, which are exploratory by nature, and the relapse-reduction finding applies to patients who had already responded during an open-label run-in, not to every person who starts treatment. Anyone considering options for a child should speak with a clinician rather than acting on trial headlines, and a large study tying ADHD to later cognitive decline is a reminder that brain-health research still turns up surprises that need careful interpretation.

A New Tourette Drug that eases tics without the metabolic and movement-related costs of current options could change daily life for school-age kids who face teasing, disrupted classrooms and the exhausting effort of holding tics in. For a field that has waited years for a genuinely new idea, a decision early next year cannot come soon enough. For more on how researchers are rethinking brain health, see our coverage of high-dose vitamin D and aging cognition.